Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]

New agents and mTOR inhibitors

Dr David Sabatini – Whitehead Institute, Boston, USA

New agents and mTOR inhibitors ( Dr David Sabatini – Whitehead Institute, Boston, USA )

New genetic sub-types of breast, ovarian and prostate cancer

Dr Paul Pharoah – University of Cambridge, UK

New genetic sub-types of breast, ovarian and prostate cancer ( Dr Paul Pharoah – University of Cambridge, UK )

Advances in the treatment of prostate cancer

Prof Malcolm Mason – Cardiff University, UK

Advances in the treatment of prostate cancer ( Prof Malcolm Mason – Cardiff University, UK )

Evolving patient management in metastatic and non-metastatic castration...

Professor Noel Clarke, Dr Heather Payne, Prof Karim Fizazi,Prof John...

Evolving patient management in metastatic and non-metastatic castration-resistant prostate cancer ( Professor Noel Clarke, Dr Heather Payne, Prof Karim Fizazi,Prof John Fitzpatrick, Prof Bertrand Tombal )

Recent evidence to support the use of aspirin in the treatment of cancer

Dr Ruth Langley – Medical Research Council, London, UK

Recent evidence to support the use of aspirin in the treatment of cancer ( Dr Ruth Langley – Medical Research Council, London, UK )

Advances in advanced renal cell carcinoma from ESMO 2012: Part 1

Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier...

Advances in advanced renal cell carcinoma from ESMO 2012: Part 1 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )

Advances in advanced renal cell carcinoma from ESMO 2012: Part 3

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard...

Advances in advanced renal cell carcinoma from ESMO 2012: Part 3 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )

Advances in advanced renal cell carcinoma from ESMO 2012: Part 2

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard...

Advances in advanced renal cell carcinoma from ESMO 2012: Part 2 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )

Genes, chromosomes and the treatment of bladder cancer

Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA

Genes, chromosomes and the treatment of bladder cancer ( Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA )

Analysing the efficacy of treatment through Response Evaluation Criteria in...

Dr Yves Menu – Saint Antoine Hospital, Paris, France

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )

Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone...

Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi

Advances in advanced prostate cancer from ESMO 2012; focus on abiraterone acetate ( Dr Chris Parker , Dr Charles Ryan, Prof Karim Fizazi )

Personalised cancer medicine and research: Today’s best practice

Prof José Baselga - Massachusetts General Hospital, Boston, USA

Personalised cancer medicine and research: Today’s best practice ( Prof José Baselga - Massachusetts General Hospital, Boston, USA )

More from ecancer